Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5
Clovis Oncology (NASDAQ: CLVS) will release its Q3 2020 financial results on November 5, 2020, before U.S. markets open. A conference call will follow at 8:30 a.m. ET to discuss the results in detail. Investors can access the live webcast via the company's website, with an archived replay available for 30 days. Clovis focuses on developing and commercializing innovative anti-cancer agents and diagnostic tools targeting specific cancer subsets.
- Scheduled announcement of Q3 2020 financial results indicates transparency.
- Live conference call allows for immediate investor engagement.
- None.
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webcast will be available for 30 days.
Conference Call Details
Clovis will hold a conference call to discuss third quarter 2020 results on Thursday, November 5 at 8:30 a.m. ET. The conference call will be simultaneously webcast on the Company’s web site at www.clovisoncology.com, and archived for future review. Dial-in numbers for the conference call are as follows: U.S. participants (877) 698-7048, International participants (647) 689-5448, conference ID: 2999168.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the U.S. and Europe.
